The Effect of ACTH (Acthar®) on Measures of Chronic Fatigue in Patients with Relapsing Multiple Sclerosis

This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.

Key Eligibilities:
-Have been treated with interferon beta 1a or 1b, glatiramer acetate (Copaxone), fingolimod (Gilenya), dimethyl fumerate (Tecfidera) or teriflunomide (Aubagio) for at least 6 months, with reported adherence rate of at least 75%, at time of screening.
-EDSS score of 0 to 4 (inclusive), MFIS ≥ 38 or FSS ≥ 36, BDI-II ≤ 19, and ESS ≤ 9.

Exclusion Criteria:
-History of sleep apnea.
-Current use of cannabis, opiates, benzodiazepines, barbiturates, gabapentin, pregabalin, topiramate, divalproex sodium, carbamazepine, oxcarbazepine, or any gaba-ergic medications other than tizanidine or Baclofen, which are permitted for spasticity treatment.

**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at clinicaltrials.gov.**
Phase IIIb
Multiple Sclerosis
Walter Carlini, M.D., Ph.D.
Providence Health & Services
Kari Jaasko
  • Providence Medford Medical Center